Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -
Prucalopride
Drug Overview
What is Prucalopride?
To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).
Request Your Assessment
Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.
View Inquiry List →Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
Regulatory Framework
Assessment Methodology
Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.
EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)
Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.
PIC/S – Shared Facilities and Contamination Control Guidance
Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.
ICH Q9 – Quality Risk Management
Provides a structured methodology for risk identification, assessment, control, communication, and review.
ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)
Applied for compounds with potential mutagenic or genotoxic concerns.
Risk-Based Toxicological Assessment
Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.
Weight-of-Evidence (WoE) Approach
Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.
How We Work
Report Preparation Process
Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.
Comprehensive Data Review
Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.
Scientific Evaluation
Identification of critical endpoints and selection of appropriate exposure limits.
PDE / HBEL Derivation
Transparent and scientifically justified calculations aligned with global toxicological principles.
Ex-Agency Expert Review (Our Differentiator)
Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.
Final Report Delivery
Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).
Ex-Agency Advantage
Why Masuu Global?
Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.
Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.
Inspection-ready reports — scientifically defensible and audit-prepared from day one.
Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).
Practical implementation recommendations that translate science into actionable contamination control.
Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.
Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.
Ready to request your assessment?
Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.
Frequently Asked Questions
Prucalopride is a serotonin 5-HT4 receptor agonist used as a medicinal substance. Its pharmacological activity and available toxicological evidence may inform assessment of potential exposure. Understanding the evidence and conditions of use helps support a documented, risk-based approach to handling.
A PDE or ADE sets a health-based limit on daily exposure to Prucalopride from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.
The assessment should be reconsidered when meaningful new toxicological data become available, the intended use or manufacturing process changes, or relevant guidance is updated. Changes in physical form, handling conditions, or exposure routes may also affect the risk assessment. A documented review helps confirm whether existing conclusions remain appropriate for the current context.
The physical form and handling conditions of Prucalopride can influence how exposure may occur. For example, powder handling may create different inhalation considerations from transferring a solution, while process steps and containment also matter. The occupational assessment should use the available information about the material and actual tasks rather than assume that one form represents every scenario.
Potential carryover is evaluated using the substance hazard assessment together with information about equipment, manufacturing sequence, product characteristics, and cleaning processes. A PDE or ADE may provide a health-based reference point where appropriate. The resulting evaluation should document its assumptions and connect the toxicological rationale with the applicable cleaning validation and contamination-control approach.
An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.
An OEB places Prucalopride in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.
Published toxicity data can be limited for some substances. The assessment can consider the quality of available evidence, relevant information from related compounds, and scientifically justified structure-based approaches where appropriate. Any read-across, assumptions, and uncertainty should be clearly documented. The strength of the conclusion must remain proportionate to the evidence and its limitations.
Where Prucalopride has relevant pharmacological activity, the assessment considers whether that activity informs the critical health effect and the interpretation of exposure-related risk. Therapeutic or mechanistic information may contribute when its quality and relevance are established, but it does not by itself determine an exposure limit. The rationale should integrate pharmacology with the broader toxicological evidence.
Therapeutic dose information may provide context when assessing a marketed active substance, but it is not sufficient on its own to establish a PDE, ADE, or OEL. The assessment must evaluate the relevant toxicological endpoints, route, population, and quality of evidence. Any use of dose information should be scientifically justified and clearly distinguished from the final exposure-limit derivation.
Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.
Use the Request Your Assessment option on this page and add Prucalopride to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.
